A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.
Public ClinicalTrials.gov record NCT04209465. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
MasterKey-01: A Phase 1/2, Open-label, Two-part, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics & Antitumor Activity of BDTX-189, an Inhibitor of Allosteric ErbB Mutations, in Patients w/ Advanced Solid Malignancies
Study identification
- NCT ID
- NCT04209465
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Black Diamond Therapeutics, Inc.
- Industry
- Enrollment
- 91 participants
Conditions and interventions
Conditions
Interventions
- BDTX-189 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 18, 2019
- Primary completion
- Sep 1, 2022
- Completion
- Sep 15, 2022
- Last update posted
- Apr 16, 2025
2019 – 2022
United States locations
- U.S. sites
- 24
- U.S. states
- 15
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 9250 | Scottsdale | Arizona | 85258 | — |
| 9405 | Long Beach | California | 90813 | — |
| 9474 | Orange | California | 92868 | — |
| 7141 | New Haven | Connecticut | 06520 | — |
| 4080 | Lake Mary | Florida | 32746 | — |
| 4100 | Orlando | Florida | 32827 | — |
| 9535 | Plantation | Florida | 33322 | — |
| 4060 | Sarasota | Florida | 34232 | — |
| 9035 | Atlanta | Georgia | 30322 | — |
| 9530 | Rolling Meadows | Illinois | 60008 | — |
| 9092 | New Orleans | Louisiana | 70112 | — |
| 9203 | Boston | Massachusetts | 02215 | — |
| 9209 | Buffalo | New York | 14263 | — |
| 9215 | New York | New York | 10016 | — |
| 9236 | New York | New York | 10065 | — |
| 9264 | Portland | Oregon | 97213 | — |
| 7122 | Pittsburgh | Pennsylvania | 15232 | — |
| 4107 | Chattanooga | Tennessee | 37404 | — |
| 3000 | Nashville | Tennessee | 37203 | — |
| 9003 | Dallas | Texas | 75390 | — |
| 9117 | Houston | Texas | 77030 | — |
| 9538 | Webster | Texas | 77598 | — |
| 9112 | Fairfax | Virginia | 22031 | — |
| 9173 | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04209465, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 16, 2025 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04209465 live on ClinicalTrials.gov.